Anna Bogatyreva

Anna Bogatyreva has a diverse work experience spanning over two decades. Anna is currently working as a Medical Director at argenx since May 2019. Prior to their current position, they worked at Pfizer as a Regional Medical Monitor from October 2010 to May 2019. Anna also has experience as a Senior CRA at Covance from March 2007 to October 2010. Before that, they worked as a Medical Project Leader at Janssen - Cilag from June 2006 to February 2007. Anna has also held roles as a CRA and Senior CRA at MB Quest, Int (Pharm-Olam Group, LTD) from January 2004 to May 2006. Anna started their career in the field of pediatrics, working as a pediatrician at the Scientific center of children health from March 2000 to June 2003 and at Orphan house #17 (hospital) from September 1998 to March 2000. Prior to that, Anna worked as a researcher and pediatrician at the Rheabilitology institute from 1996 to 1998.

Anna Bogatyreva's education history is as follows:

- In 2023, they attended Harvard Medical School and studied Gene Therapy.

- Anna also attended Harvard Medical School in 2023, but the field of study is not specified.

- From 2012 to 2014, they pursued a postgraduate course in Pharmaceutical medicine at Cardiff University / Prifysgol Caerdydd.

- In 2000, they obtained their PhD from The Russian State Medical University, specializing in osteoporosis in children.

- In 1999, they completed a Neurology Residency Program at MONIKI and received a neurologist certificate.

- In 1995, they obtained a pediatrician degree from the First Moscow State Medical University named after I.M. Sechenov.

- Anna also holds an additional certification in Paediatric Drug Development & Clinical Trials, which they obtained in June 2023 from Symmetric Training.